149
Participants
Start Date
March 5, 2013
Primary Completion Date
June 30, 2014
Study Completion Date
January 27, 2017
ASKP1240
intravenous infusion
Tacrolimus
intravenous or oral
Mycophenolate Mofetil (MMF)
intravenous or oral
Basiliximab
intravenous
Methylprednisone
Intravenous
Prednisone
Oral
Site US10034, New York
Site US10023, New York
Site US10019, The Bronx
Site US10031, Buffalo
Site US10038, Pittsburgh
Site US10027, Harrisburg
Site US10014, Baltimore
Site US10020, Charlottesville
Site US10036, Chapel Hill
Site US10016, Durham
Site US10026, Greenville
Site US10042, Charlotte
Site US10012, Charleston
Site US10007, Atlanta
Site US10041, Augusta
Site US10006, Birmingham
Site US10028, Memphis
Site US10015, Lexington
Site US10040, Cleveland
Site US10032, Cleveland
Site US10009, Cincinnati
Site US10017, Ann Arbor
Site US10005, Madison
Site US10010, Chicago
Site US10018, Chicago
Site US10037, Chicago
Site US10025, St Louis
Site US10045, New Orleans
Site US10001, Dallas
Site US10002, Fort Worth
Site US10029, Houston
Site US10044, Houston
Site US10013, Aurora
Site US10033, Salt Lake City
Site US10024, Phoenix
Site US10008, Los Angeles
Site US10030, San Diego
Site US10004, San Francisco
Site US10003, San Francisco
Site US10021, Palo Alto
Site US10022, Livingston
Site US10035, Nashville
Kyowa Kirin Co., Ltd.
INDUSTRY
Astellas Pharma Global Development, Inc.
INDUSTRY